@article {Annavajhala2021.02.23.21252259, author = {Medini K. Annavajhala and Hiroshi Mohri and Jason E. Zucker and Zizhang Sheng and Pengfei Wang and Angela Gomez-Simmonds and David D. Ho and Anne-Catrin Uhlemann}, title = {A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York}, elocation-id = {2021.02.23.21252259}, year = {2021}, doi = {10.1101/2021.02.23.21252259}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Recent months have seen surges of SARS-CoV-2 infection across the globe along with considerable viral evolution. Extensive mutations in the spike protein of variants B.1.1.7, B1.351, and P.1 have raised concerns that the efficacy of current vaccines and therapeutic monoclonal antibodies could be threatened. In vitro studies have shown that one mutation, E484K, plays a crucial role in the loss of neutralizing activity of some monoclonal antibodies as well as most convalescent and vaccinee sera against variant B.1.351. In fact, two vaccine trials have recently reported lower protective efficacy in South Africa, where B.1.351 is dominant. To survey for these novel variants in our patient population in New York City, PCR assays were designed to identify viruses with two signature mutations, E484K and N501Y. We observed a steady increase in the detection rate from late December to mid-February, with an alarming rise to 12.3\% in the past two weeks. Whole genome sequencing further demonstrated that most of our E484K isolates (n=49/65) fell within a single lineage: NextStrain clade 20C or Pangolin lineage B.1.526. Patients with this novel variant came from diverse neighborhoods in the metropolitan area, and they were on average older and more frequently hospitalized. Phylogenetic analyses of sequences in the database further reveal that this B.1.526 variant is scattered in the Northeast of US, and its unique set of spike mutations may also pose an antigenic challenge for current interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBiospecimens utilized for this research were obtained from the Columbia University Biobank (CUB), supported by the Irving Institute for Clinical and Translational Research, home to Columbia University Clinical and Translational Science Award (CTSA) funded through Grant Number UL1TR001873. This work was in part funded by NIH/NIDA grant U01 DA053949 (ACU, MKA) and by support from Andrew \& Peggy Cherng, Samuel Yin, Barbara Picower and the JBP Foundation, Brii Biosciences, Roger \& David Wu, and the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Columbia University Institutional Review Board (protocol number AAAT0123).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 genomes generated as part of this study have been submitted to GISAID on 2/23/2021.}, URL = {https://www.medrxiv.org/content/early/2021/02/25/2021.02.23.21252259}, eprint = {https://www.medrxiv.org/content/early/2021/02/25/2021.02.23.21252259.full.pdf}, journal = {medRxiv} }